Zhonghua Xue Ye Xue Za Zhi. 2025 Feb 14;46(2):105-112. doi: 10.3760/cma.j.cn121090-20241209-00551.
Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL) is a mature B cell neoplasm with specific immunophenotype, mainly occurs in the middle-aged and elderly population. In recent years, there has been significant progress in the basic and clinical research of CLL/SLL, especially in the field of new drug treatments. To improve the diagnostic, differential diagnostic, and standardized treatment levels of CLL/SLL for medical workers in China, Hematological Oncology Committee of China Anti-Cancer Association, Hematology Committee of Chinese Medical Association, Chinese Working Group for Chronic Lymphocytic Leukemia have revised the guidelines for the diagnosis and treatment of Chinese CLL/SLL (2022 edition) and formulated this version of the guidelines.
慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）是一种具有特定免疫表型的成熟B细胞肿瘤，主要发生于中老年人群。近年来，CLL/SLL的基础与临床研究取得了显著进展，尤其是在新药治疗领域。为提高我国医务工作者对CLL/SLL的诊断、鉴别诊断及规范化治疗水平，中国抗癌协会血液肿瘤专业委员会、中华医学会血液学分会、中国慢性淋巴细胞白血病工作组对《中国CLL/SLL诊断与治疗指南（2022年版）》进行修订，制定了本版指南。
